Passage Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences:

TD Cowen 44th Annual Health Care ConferenceFormat: Management will participate in a panel and investor meetingsDate: Tuesday, March 5, 2024Time: 10:30 a.m. ET Location: Boston, MA

Leerink Partners Global Biopharma Conference Format: Management will participate in investor meetingsDate: Wednesday, March 13, 2024Location: Miami, FL

A live webcast of the panel discussion will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the panel will be available for 30 days following the event.

About Passage Bio

Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.

To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: www.passagebio.com.

For further information, please contact:

Investors:Stuart HendersonPassage Bio267.866.0114[email protected]

Passage Bio Media:Mike BeyerSam Brown Inc. Healthcare Communications312.961.2502[email protected]

You May Also Be Interested In

• Bang & Olufsen appoints new executive leadership team
• First six months 2026 interim report: sustained strategic progress and consistent financial performance. Full-year 2026 guidance for Adjusted EBITDA and Investments reiterated
• Appinventiv Accelerates Healthcare IT Modernization with EHR and EMR Software Solutions